|
Nov 1
|
Stocks to watch next week: Berkshire Hathaway, Super Micro, Novo Nordisk, Vistry and M&S
|
|
Nov 1
|
Ahead of Gilead (GILD) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
|
|
Oct 31
|
AbTherx and Gilead Expand Collaboration on Innovative Antibody Discovery Technologies
|
|
Oct 30
|
Earnings Preview: Gilead Sciences (GILD) Q3 Earnings Expected to Decline
|
|
Oct 9
|
Gilead Sciences Inc (GILD) Q2 2024 Earnings Call Highlights: Strong Growth in HIV and Oncology ...
|
|
Oct 9
|
Gilead Sciences to Release Third Quarter 2024 Financial Results on Wednesday, November 6, 2024
|
|
Oct 9
|
Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024
|
|
Oct 8
|
Gilead Sciences (GILD) Increases Yet Falls Behind Market: What Investors Need to Know
|
|
Oct 7
|
Gilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference
|
|
Oct 7
|
AstraZeneca and Gilead Sciences merger would be the biggest in the pharma history
|
|
Oct 5
|
Gilead Sciences' (NASDAQ:GILD) investors will be pleased with their favorable 62% return over the last five years
|
|
Oct 4
|
Praxis Precision Medicines (PRAX) Moves 8.4% Higher: Will This Strength Last?
|
|
Oct 3
|
GILD Grants Right for HIV PrEP Candidate to Six Generic Companies
|
|
Oct 3
|
Gilead signs agreements to facilitate access to HIV prevention drug
|
|
Oct 2
|
Hetero Signs Voluntary Licensing Agreement with Gilead to Transform Global HIV response, Expanding Access to Groundbreaking Lenacapavir to 120 high-incidence countries
|
|
Oct 2
|
Gilead Signs Royalty-Free Voluntary Licensing Agreements With Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countries
|
|
Sep 25
|
Championing HIV Services for LGBTQ+ Youth
|
|
Sep 24
|
Gilead Sciences (GILD) Stock Slides as Market Rises: Facts to Know Before You Trade
|
|
Sep 23
|
AstraZeneca Stock Dips On Surprise Miss For Gilead-Rivaling Cancer Drug
|
|
Sep 23
|
Gilead Sciences Recalls One Lot Of Its COVID-19 Treatment Due To Presence Of Glass Particles
|